Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118747 | 0.80 | DRD4 (0.45) | NPY5RCYP19A1 | |
| SCHEMBL152894 | 0.73 | KDM4E (0.41) | L3MBTL1 | |
| SCHEMBL30724388 | 0.71 | CHRM2 (0.41) | NPY5RCYP19A1DUSP10L3MBTL1 | |
| SCHEMBL3617507 | 0.69 | — | — | |
| SCHEMBL467418 | 0.69 | CYP2A6 (0.42) | NPY5RCYP19A1L3MBTL1 | |
| SCHEMBL467462 | 0.69 | BCHE (0.41) | — | |
| SCHEMBL149347 | 0.67 | — | — | |
| SCHEMBL29395766 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL695996 | 0.66 | TSHR (0.40) | NPY5RCYP19A1L3MBTL1 | |
| SCHEMBL3602680 | 0.66 | GAA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | disclosed |
| EP-4132652-A1 | AXL INHIBITORS FOR ANTIVIRAL THERAPY | BerGenBio ASA (NO) | 2023-02-15 | — | — | EP | disclosed |
| EP-4125908-A1 | COMBINATION THERAPY COMPRISING AN AXL INHIBITOR | BerGenBio ASA (NO) | 2023-02-08 | — | — | EP | disclosed |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | BERGENBIO ASA (NO) | 2022-12-27 | — | — | US | disclosed |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | MIDCAP FINANCIAL TRUST | 2021-12-09 | — | — | US | disclosed |
| WO-2021214492-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BERGENBIO ASA (NO) | 2021-10-28 | — | — | WO | disclosed |
| EP-3302481-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BerGenBio ASA (NO) | 2018-04-11 | — | — | EP | disclosed |
| US-20170042891-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| WO-2016193680-A1 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS | BERGENBIO AS (NO) | 2016-12-08 | — | — | WO | disclosed |
| EP-2387395-B1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130338161-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8546433-B2 | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010083465-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196511-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | NPY5R 2603/4885CYP19A1 4044/4885TBXAS1 2983/4885 |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | NPY5R 2927/4885CYP19A1 4503/4885TBXAS1 4426/4885 |
| US-11534440-B2 | Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus | AXL, CD274, HAVCR2 | NPY5R 3429/4885CYP19A1 4518/4885TBXAS1 4512/4885 |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | AXL, CD274, CD47 | NPY5R 3502/4885CYP19A1 4422/4885TBXAS1 4090/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | NPY5R 3017/4885CYP19A1 4234/4885TBXAS1 2401/4885 |
| US-20170042891-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | NPY5R 2603/4885CYP19A1 4044/4885TBXAS1 2983/4885 |
| US-20210379064-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | NPY5R 2603/4885CYP19A1 4044/4885TBXAS1 2983/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | NPY5R 3126/4885CYP19A1 3045/4885TBXAS1 3259/4885 |
| US-20130338161-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | AXL, FLT3, MET | NPY5R 2603/4885CYP19A1 4044/4885TBXAS1 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.